The inherited retinal disease (IRD) community, particularly those affected by Stargardt Disease Type 1 (STGD1), has received promising news. Belite Bio has announced the completion of its rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for tinlarebant, an investigational oral therapy for STGD1. This marks a significant step forward as there are currently no approved pharmacologic treatments for this condition.
A Potential First-in-Class Treatment for Stargardt Disease Type 1
Stargardt Disease Type 1 is a rare, inherited retinal disease caused by mutations in the ABCA4 gene, leading to progressive and irreversible vision loss, often beginning in childhood or early adulthood. It affects an estimated 53,000 people in the U.S. alone. Tinlarebant (LBS-008) is a once-daily oral therapy designed to reduce the accumulation of toxic vitamin A-derived by-products in the retina, which are implicated in the degeneration seen in STGD1.
The rolling NDA submission, initiated in April 2026, was conducted under Breakthrough Therapy Designation (BTD), a status granted by the FDA to expedite the development and review of drugs for serious or life-threatening conditions where preliminary clinical evidence indicates substantial improvement over available therapies. Tinlarebant has also received Fast Track Designation and Rare Pediatric Disease Designation in the U.S., as well as Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland.
What This Means for Patients and Families
The completed NDA will now undergo a 60-day review period by the FDA. If accepted, a Prescription Drug User Fee Act (PDUFA) target action date will be assigned, which will set a timeline for a potential approval decision. The submission is supported primarily by data from the Phase 3 DRAGON trial, which reportedly met its primary endpoint by demonstrating a statistically significant reduction in the rate of retinal lesion growth compared to placebo.
Dr. Tom Lin, Chairman and Chief Executive Officer of Belite Bio, highlighted the significance of this milestone, stating that it represents an important step forward for those affected by Stargardt disease who have long faced progressive vision loss without an approved treatment option. Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio, added that Stargardt disease places a profound burden on patients, often affecting them early in life and steadily diminishing central vision during critical years of education and independence.
Looking Ahead
While the FDA's review process is underway, the completion of this submission brings the STGD1 community closer to a potential first pharmacologic treatment. The coming months will be crucial as the FDA evaluates the application, and the community eagerly awaits further updates on tinlarebant's path to potential approval.